Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Patients with Chronic Rhinosinusitis with Nasal Polyps
NCT04805398Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing CM310 Arm with Placebo Arm (2 arms). Primary endpoints: Bilateral Endoscopic Nasal Polyps Score at 16 weeks and Nasal Congestion/Obstruction Symptom Severity Score at 16 weeks. Started Apr 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT04805398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805398.